This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deguchi, A. Articles by Weinstein, I. B. Search for Related Content PubMed PubMed Citation Articles by Deguchi, A. Articles by Weinstein, I. B.

Activation of Protein Kinase G Up-regulates Expression of 15-Lipoxygenase-1 in Human Colon Cancer Cells

¹ Department of Medicine and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center; ² Department of Pharmacology, Columbia University Medical Center, New York; ³ OSI Pharmaceuticals, Inc., Farmingdale, New York; and Departments of ⁴ Clinical Cancer Prevention and ⁵ Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: I. Bernard Weinstein, Department of Medicine and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, 701 West 168th Street, HHSC-1509, New York, NY 10032. Phone: 212-305-6921; Fax: 212-305-6889; E-mail: ibw1{at}columbia.edu.

Recent studies indicate that the induction of apoptosis in human colon cancer cells by certain nonsteroidal antiinflammatory drugs involves increased expression of 15-LOX-1 and synthesis of its major product 13-S-hydroxyoctadecadienoic acid (13-S-HODE). Evidence was obtained that this occurs via a cyclooxygenase-2 (COX-2)–independent mechanism, but the actual mechanism of induction of 15-LOX-1 by these compounds is not known. There is extensive evidence that treatment of SW480 human colon cancer cells with sulindac sulfone (Exisulind, Aptosyn) or the related derivative OSI-461, both of which inhibit cyclic GMP (cGMP)-phosphodiesterases but lack COX-2 inhibitory activity, causes an increase in intracellular levels of cGMP, thus activating protein kinase G (PKG), which then activates pathways that lead to apoptosis. Therefore, in the present study, we examined the effects of various agents that cause increased cellular levels of cGMP on the expression of 15-LOX-1 in SW480 human colon cancer cells. Treatment of the cells with Exisulind, sulindac sulfide, OSI-461, the guanylyl cyclase activator YC-1, or the cell-permeable cGMP compound 8-para-chlorophenylthio-cGMP (8-pCPT-cGMP) caused an increase in cellular levels of 15-LOX-1. Exisulind, OSI-461, and 8-pCPT-cGMP also increased mRNA levels of 15-LOX-1, suggesting that the effects were at the level of transcription. The cGMP-phosphodiesterase inhibitors and YC-1 increased the production of 13-S-HODE, which is the linoleic acid metabolite of 15-LOX-1. Treatment of SW480 cells with the PKG inhibitor Rp-8-pCPT-cGMP blocked Exisulind-induced 15-LOX-1 expression. Furthermore, derivatives of SW480 cells that were engineered to stably overexpress wild-type PKG Iß displayed increased cellular levels of 15-LOX-1 when compared with vector control cells. Taken together, these results provide evidence that the cGMP/PKG pathway can play an important role in the induction of 15-LOX-1 expression by nonsteroidal antiinflammatory drugs and related agents.

This article has been cited by other articles:

				X. Zuo, J. S. Morris, and I. Shureiqi Chromatin Modification Requirements for 15-Lipoxygenase-1 Transcriptional Reactivation in Colon Cancer Cells J. Biol. Chem., November 14, 2008; 283(46): 31341 - 31347. [Abstract] [Full Text] [PDF]

				B. Cen, A. Deguchi, and I. B. Weinstein Activation of Protein Kinase G Increases the Expression of p21CIP1, p27KIP1, and Histidine Triad Protein 1 through Sp1 Cancer Res., July 1, 2008; 68(13): 5355 - 5362. [Abstract] [Full Text] [PDF]

				X. Zuo, L. Shen, J.-P. Issa, O. Moy, J. S. Morris, S. M. Lippman, and I. Shureiqi 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation FASEB J, June 1, 2008; 22(6): 1981 - 1992. [Abstract] [Full Text] [PDF]

				X. Tang, N. Aggarwal, B. B. Holmes, H. Kuhn, and W. B. Campbell Age-related decrease in 15-lipoxygenase contributes to reduced vasorelaxation in rabbit aorta Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H679 - H687. [Abstract] [Full Text] [PDF]

				L. Ying, A. B. Hofseth, D. D. Browning, M. Nagarkatti, P. S. Nagarkatti, and L. J. Hofseth Nitric Oxide Inactivates the Retinoblastoma Pathway in Chronic Inflammation Cancer Res., October 1, 2007; 67(19): 9286 - 9293. [Abstract] [Full Text] [PDF]

				I. Shureiqi, X. Zuo, R. Broaddus, Y. Wu, B. Guan, J. S. Morris, and S. M. Lippman The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer FASEB J, March 1, 2007; 21(3): 743 - 753. [Abstract] [Full Text] [PDF]

				J. T.E. Lim, A. K. Joe, M. Suzui, M. Shimizu, M. Masuda, and I. B. Weinstein Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells. Clin. Cancer Res., June 1, 2006; 12(11): 3478 - 3484. [Abstract] [Full Text] [PDF]

				S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF]